- Home
- TALO vs MESO Comparison
TALO vs MESO Comparison
Compare TALO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALO
- MESO
- Stock Information
- Founded
- TALO 2011
- MESO 2004
- Country
- TALO United States
- MESO Australia
- Employees
- TALO N/A
- MESO N/A
- Industry
- TALO Oil & Gas Production
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TALO Energy
- MESO Health Care
- Exchange
- TALO Nasdaq
- MESO Nasdaq
- Market Cap
- TALO N/A
- MESO 1.7B
- IPO Year
- TALO N/A
- MESO N/A
- Fundamental
- Price
- TALO $9.72
- MESO $12.48
- Analyst Decision
- TALO Strong Buy
- MESO Buy
- Analyst Count
- TALO 9
- MESO 4
- Target Price
- TALO $15.56
- MESO $18.00
- AVG Volume (30 Days)
- TALO 1.9M
- MESO 305.9K
- Earning Date
- TALO 05-05-2025
- MESO 02-26-2025
- Dividend Yield
- TALO N/A
- MESO N/A
- EPS Growth
- TALO N/A
- MESO N/A
- EPS
- TALO N/A
- MESO N/A
- Revenue
- TALO $1,972,191,000.00
- MESO $5,670,000.00
- Revenue This Year
- TALO N/A
- MESO $228.57
- Revenue Next Year
- TALO N/A
- MESO $356.77
- P/E Ratio
- TALO N/A
- MESO N/A
- Revenue Growth
- TALO 35.51
- MESO N/A
- 52 Week Low
- TALO $8.05
- MESO $4.60
- 52 Week High
- TALO $14.67
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- TALO 63.14
- MESO 34.58
- Support Level
- TALO $9.01
- MESO $13.60
- Resistance Level
- TALO $9.74
- MESO $14.45
- Average True Range (ATR)
- TALO 0.32
- MESO 0.49
- MACD
- TALO 0.14
- MESO 0.02
- Stochastic Oscillator
- TALO 89.76
- MESO 23.50
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.